BridgeBio Pharma Stock Forecast

Stock Price Forecast

According to 22 analysts polled by S&P Global, BridgeBio Pharma stock has a consensus rating of "Buy" and an average price target of $108.43. The average 1-year stock price forecast is 36.61% higher than the current stock price, while the lowest is $80 (+0.79%) and the highest is $157 (+97.81%).

Price Target: $108.43 (+36.61%)

Analyst Consensus: Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$80	$108.43	$108	$157
Change	+0.79%	+36.61%	+36.07%	+97.81%

Analyst Ratings

The average analyst rating for BridgeBio Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart

Rating	Mar '26	Apr '26	May '26	Jun '26	Jul '26	Aug '26
Strong Buy	16	16	15	16	14	14
Buy	5	6	6	6	6	5
Hold	1	1	2	2	2	3
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	22	23	23	24	22	22

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Luca Issi RBC Capital	RBC Capital	Buy Maintains $100	Buy	Maintains	$100	+25.99%	Aug 14, 2026
Whitney Ijem Canaccord Genuity	Canaccord Genuity	Buy Maintains $104 → $106	Buy	Maintains	$104 → $106	+33.55%	Aug 12, 2026
Eric Joseph Citi	Citi	Hold Maintains $93 → $94	Hold	Maintains	$93 → $94	+18.43%	Aug 12, 2026
Eliana Merle Barclays	Barclays	Buy Maintains $157	Buy	Maintains	$157	+97.81%	Aug 12, 2026
Anupam Rama J.P. Morgan	J.P. Morgan	Buy Reiterates $100 → $111	Buy	Reiterates	$100 → $111	+39.85%	Aug 11, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

1.01B

from 502.08M

102.08%

from 502.08M

Revenue Next Year

1.69B

from 1.01B

67.04%

from 1.01B

EPS This Year

-2.68

from -3.78

EPS Next Year

0.15

from -2.68

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	69.72M	77.65M	9.30M	221.90M	502.08M	1.01B
Revenue Growth	745.15%	11.38%	-88.02%	2,285.27%	126.26%	102.08%
Gross Profit	66.60M	74.21M	6.86M	218.02M	481.11M	953.74M
Gross Margin	95.53%	95.58%	73.71%	98.25%	95.82%	94.00%
Operating Income	-573.33M	-468.44M	-599.44M	-577.37M	-502.06M	-375.40M
Net Income	-562.54M	-481.18M	-643.20M	-535.76M	-724.93M	-549.88M
EPS	-	-	-	-	-3.78	-2.68
Free Cash Flow	-301.13M	-285.88M	-240.16M	-291.12M	-325.29M	-316.56M
No. Analysts	-	-	-	-	-	19

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	1.1B
Avg	1.0B
Low	965.0M

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	118.6%
Avg	102.1%
Low	92.2%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-2.24
Avg	-2.68
Low	-2.91

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-